<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795283</url>
  </required_header>
  <id_info>
    <org_study_id>21C222</org_study_id>
    <nct_id>NCT05795283</nct_id>
  </id_info>
  <brief_title>Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Anorexia Nervosa.</brief_title>
  <acronym>ANCITA</acronym>
  <official_title>Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Patients With Anorexia Nervosa: a Single-center Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Auxologico Italiano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Auxologico Italiano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients suffering from anorexia nervosa associated with severe major depression,&#xD;
      serotonin reuptake inhibitor drugs have shown little efficacy in significantly reducing&#xD;
      depressive symptoms. A possible explanation for this poor efficacy could be that people with&#xD;
      anorexia nervosa have a deficiency in amino acids such as tryptophan, which is necessary for&#xD;
      the production of the neurotransmitter serotonin. Therefore, tryptophan supplementation has&#xD;
      been suggested as a means of increasing the pharmacological response to serotonin reuptake&#xD;
      inhibitor drugs in patients with anorexia nervosa. Furthermore, malnutrition present in&#xD;
      patients suffering from anorexia nervosa is in some cases associated with problems of&#xD;
      intestinal absorption of nutrients, with possible implications on the pharmacokinetics of the&#xD;
      drugs administered, including selective serotonin reuptake inhibitors (SSRIs).&#xD;
&#xD;
      The present observational study aims to evaluate the correlations between the clinical&#xD;
      response to Citalopram therapy (in different o.s. and i.v. formulations) and some&#xD;
      nutritional, neurotransmitter and inflammatory biomarkers, in order to identify potential&#xD;
      predictive markers of response to therapy for severe major depression in patients with&#xD;
      anorexia nervosa.&#xD;
&#xD;
      The following parameters will be evaluated in patients enrolled in all 3 observation times&#xD;
      described above:&#xD;
&#xD;
        -  Plasma concentration of Citalopram&#xD;
&#xD;
        -  Serum concentration of Serotonin&#xD;
&#xD;
        -  Plasma concentration of dopamine&#xD;
&#xD;
        -  Serum concentration of Tryptophan&#xD;
&#xD;
        -  Serum concentration of BDNF&#xD;
&#xD;
        -  Hamilton scale 17 items and other clinical scales (EDI-3, SCL-90, BUT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2022</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Rating Scale</measure>
    <time_frame>At baseline, 2 weeks and 4 weeks after treatment with citalopram</time_frame>
    <description>17-item Hamilton Depression Rating Scale -</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma level of citalopram</measure>
    <time_frame>At baseline, 2 weeks and 4 weeks after treatment with citalopram</time_frame>
    <description>Plasma level of citalopram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma level of dopamine</measure>
    <time_frame>At baseline, 2 weeks and 4 weeks after treatment with citalopram</time_frame>
    <description>Plasma level of dopamine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum level of serotonin</measure>
    <time_frame>At baseline, 2 weeks and 4 weeks after treatment with citalopram</time_frame>
    <description>Serum level of serotonin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum level of brain-derived neurotrophic factor</measure>
    <time_frame>At baseline, 2 weeks and 4 weeks after treatment with citalopram</time_frame>
    <description>Serum level of brain-derived neurotrophic factor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum level of tryptophan</measure>
    <time_frame>At baseline, 2 weeks and 4 weeks after treatment with citalopram</time_frame>
    <description>Serum level of tryptophan</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Group A: Citalopram i.v. and p.o</arm_group_label>
    <description>Both intravenous and oral administration of citalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Citalopram p.o</arm_group_label>
    <description>Oral administration of citalopram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram i.v. and p.o</intervention_name>
    <description>Citalopram:&#xD;
i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28</description>
    <arm_group_label>Group A: Citalopram i.v. and p.o</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram p.o</intervention_name>
    <description>Citalopram:&#xD;
p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28</description>
    <arm_group_label>Group B: Citalopram p.o</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with anorexia nervosa and severe depression&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Anorexia nervosa&#xD;
&#xD;
          -  Severe depression (Hamilton score 25 or higher)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other psychiatric disorders&#xD;
&#xD;
          -  Acute infectious diseases&#xD;
&#xD;
          -  Chronic inflammatory diseases&#xD;
&#xD;
          -  Disorders of central nervous system&#xD;
&#xD;
          -  Pregnancy ore breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Riccardo Cremascoli, MD</last_name>
    <phone>+393497292068</phone>
    <email>r.cremascoli@auxologico.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Auxologico Italiano</name>
      <address>
        <city>Oggebbio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Cremascoli, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major depression</keyword>
  <keyword>Citalopram</keyword>
  <keyword>Biological markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

